Melanoma patient derived xenografts acquire distinct Vemurafenib resistance mechanisms

Variable clinical responses, tumor heterogeneity, and drug resistance reduce long-term survival outcomes for metastatic melanoma patients. To guide and accelerate drug development, we characterized tumor responses for five melanoma patient derived xenograft models treated with Vemurafenib. Three BRA...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Am J Cancer Res
Asıl Yazarlar: Monsma, David J, Cherba, David M, Eugster, Emily E, Dylewski, Dawna L, Davidson, Paula T, Peterson, Chelsea A, Borgman, Andrew S, Winn, Mary E, Dykema, Karl J, Webb, Craig P, MacKeigan, Jeffrey P, Duesbery, Nicholas S, Nickoloff, Brian J, Monks, Noel R
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: e-Century Publishing Corporation 2015
Konular:
Original Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4473327/
https://ncbi.nlm.nih.gov/pubmed/26101714
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller